首页 > 最新文献

Pleura and Peritoneum最新文献

英文 中文
Peritoneal mestastases from rare ovarian cancer treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS/HIPEC) 用细胞切除手术和腹腔热化疗(CRS/HIPEC)治疗罕见卵巢癌腹膜转移灶
IF 1.8 Q4 ONCOLOGY Pub Date : 2023-12-27 DOI: 10.1515/pp-2023-0019
Luis Felipe Falla-Zuniga, A. Sardi, M. King, F. Lopez-Ramirez, Philipp Barakat, C. Nieroda, T. Diaz-Montes, V. Gushchin
Abstract Objective There are limited treatment options and no consensus on the management of advanced rare ovarian malignancies. Rare ovarian malignancies can present with peritoneal metastases (PM), featuring a similar presentation to more common ovarian subtypes. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS/HIPEC) is an effective treatment for PM of non-gynecologic origin and, recently, epithelial ovarian cancer. We evaluated the feasibility of CRS/HIPEC in the management of PM from rare ovarian malignancies and report postoperative outcomes on these patients. Methods A retrospective review of a single center, prospective database (1994–2021) was performed to identify patients with rare ovarian malignancies treated with CRS/HIPEC. Clavien-Dindo 90-day morbidity/mortality and Kaplan–Meier overall (OS) and progression-free survival (PFS) were analyzed. Results Of 44 patients identified, 28 underwent CRS/HIPEC. Six were aborted due to extensive disease. Histologic subtypes included: clear cell (5/28, 17.9 %), endometrioid (5/28, 17.9 %), granulosa cell (3/28, 10.7 %), low-grade serous (6/28, 21.4 %), mesonephric (1/28, 3.6 %), mucinous (6/28, 21.4 %), and small cell (2/28, 7.1 %) carcinomas. Eight (28.6 %) patients had primary and 20 (71.4 %) had recurrent disease. Median peritoneal cancer index (PCI) was 21 (IQR: 6–29). Complete cytoreduction (<2.5 mm residual disease) was achieved in 27/28 (96.4 %). Grade III/IV complications occurred in 9/28 (32.1 %) with one (3.6 %) mortality. After a median follow-up of 65.8 months, 20 patients were alive. Five-year OS and PFS were 68.5 and 52.6 %, respectively. Conclusions In patients with PM from rare ovarian malignancies, CRS/HIPEC is feasible and has an acceptable safety profile. Longer follow-up and multicenter trials are needed.
摘要 目的 对于晚期罕见卵巢恶性肿瘤的治疗,目前治疗方案有限,且尚未达成共识。罕见卵巢恶性肿瘤可出现腹膜转移(PM),其表现与常见卵巢亚型相似。细胞切除手术和腹腔内热化疗(CRS/HIPEC)是治疗非妇科源性卵巢癌以及最近上皮性卵巢癌的有效方法。我们评估了 CRS/HIPEC 治疗罕见卵巢恶性肿瘤的可行性,并报告了这些患者的术后效果。方法 我们对单个中心的前瞻性数据库(1994-2021 年)进行了回顾性审查,以确定接受 CRS/HIPEC 治疗的罕见卵巢恶性肿瘤患者。分析了 Clavien-Dindo 90 天发病率/死亡率、Kaplan-Meier 总生存期(OS)和无进展生存期(PFS)。结果 在确定的 44 名患者中,28 人接受了 CRS/HIPEC。6例患者因病变广泛而流产。组织学亚型包括:透明细胞癌(5/28,17.9%)、类子宫内膜癌(5/28,17.9%)、颗粒细胞癌(3/28,10.7%)、低级别浆液性癌(6/28,21.4%)、间质细胞癌(1/28,3.6%)、粘液腺癌(6/28,21.4%)和小细胞癌(2/28,7.1%)。8名患者(28.6%)患有原发性疾病,20名患者(71.4%)患有复发性疾病。腹膜癌指数(PCI)中位数为 21(IQR:6-29)。27/28(96.4%)名患者实现了完全细胞减灭术(残留病灶小于 2.5 毫米)。9/28(32.1%)例出现了 III/IV 级并发症,其中 1 例(3.6%)死亡。中位随访 65.8 个月后,20 名患者存活。五年的OS和PFS分别为68.5%和52.6%。结论 对于罕见卵巢恶性肿瘤 PM 患者,CRS/HIPEC 是可行的,其安全性也是可以接受的。需要进行更长时间的随访和多中心试验。
{"title":"Peritoneal mestastases from rare ovarian cancer treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS/HIPEC)","authors":"Luis Felipe Falla-Zuniga, A. Sardi, M. King, F. Lopez-Ramirez, Philipp Barakat, C. Nieroda, T. Diaz-Montes, V. Gushchin","doi":"10.1515/pp-2023-0019","DOIUrl":"https://doi.org/10.1515/pp-2023-0019","url":null,"abstract":"Abstract Objective There are limited treatment options and no consensus on the management of advanced rare ovarian malignancies. Rare ovarian malignancies can present with peritoneal metastases (PM), featuring a similar presentation to more common ovarian subtypes. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS/HIPEC) is an effective treatment for PM of non-gynecologic origin and, recently, epithelial ovarian cancer. We evaluated the feasibility of CRS/HIPEC in the management of PM from rare ovarian malignancies and report postoperative outcomes on these patients. Methods A retrospective review of a single center, prospective database (1994–2021) was performed to identify patients with rare ovarian malignancies treated with CRS/HIPEC. Clavien-Dindo 90-day morbidity/mortality and Kaplan–Meier overall (OS) and progression-free survival (PFS) were analyzed. Results Of 44 patients identified, 28 underwent CRS/HIPEC. Six were aborted due to extensive disease. Histologic subtypes included: clear cell (5/28, 17.9 %), endometrioid (5/28, 17.9 %), granulosa cell (3/28, 10.7 %), low-grade serous (6/28, 21.4 %), mesonephric (1/28, 3.6 %), mucinous (6/28, 21.4 %), and small cell (2/28, 7.1 %) carcinomas. Eight (28.6 %) patients had primary and 20 (71.4 %) had recurrent disease. Median peritoneal cancer index (PCI) was 21 (IQR: 6–29). Complete cytoreduction (<2.5 mm residual disease) was achieved in 27/28 (96.4 %). Grade III/IV complications occurred in 9/28 (32.1 %) with one (3.6 %) mortality. After a median follow-up of 65.8 months, 20 patients were alive. Five-year OS and PFS were 68.5 and 52.6 %, respectively. Conclusions In patients with PM from rare ovarian malignancies, CRS/HIPEC is feasible and has an acceptable safety profile. Longer follow-up and multicenter trials are needed.","PeriodicalId":20231,"journal":{"name":"Pleura and Peritoneum","volume":"4 4","pages":""},"PeriodicalIF":1.8,"publicationDate":"2023-12-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139153728","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Implementation of ERAS guidelines in patients undergoing CRS and HIPEC: need for multicentre trial 在接受 CRS 和 HIPEC 治疗的患者中实施 ERAS 指南:需要进行多中心试验
IF 1.8 Q4 ONCOLOGY Pub Date : 2023-12-20 DOI: 10.1515/pp-2023-0022
C. Iavazzo, I. Gkegkes, J. Spiliotis
{"title":"Implementation of ERAS guidelines in patients undergoing CRS and HIPEC: need for multicentre trial","authors":"C. Iavazzo, I. Gkegkes, J. Spiliotis","doi":"10.1515/pp-2023-0022","DOIUrl":"https://doi.org/10.1515/pp-2023-0022","url":null,"abstract":"","PeriodicalId":20231,"journal":{"name":"Pleura and Peritoneum","volume":"111 21","pages":""},"PeriodicalIF":1.8,"publicationDate":"2023-12-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138954045","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Second annual report from the ISSPP PIPAC database ISSPP PIPAC 数据库第二次年度报告
IF 1.8 Q4 ONCOLOGY Pub Date : 2023-12-13 DOI: 10.1515/pp-2023-0047
Michael Bau Mortensen, Francesco Casella, Özgül Düzgün, Olivier Glehen, Peter Hewett, Martin Hübner, Magnus Skov Jørgensen, Alfred Königsrainer, Miguel Marin, M. Pocard, Günther Rezniczek, Jimmy So, C. Fristrup
Abstract Objectives To monitor the results of PIPAC directed therapy based on data from the International Society for the Study of the Pleura and Peritoneum (ISSPP) PIPAC database. Methods Analysis of data from patients entered between June 15th, 2020, and February 28th, 2023. Results Twelve centers reported 2,456 PIPAC procedures in 809 patients (median 2, range 1–18) with peritoneal metastasis (PM) from different primary tumors. Approximately 90 % had systemic chemotherapy prior to PIPAC. Twenty-eight percent were treated in prospective protocols. Overall non-access rate was 3.5 %. Concomitant surgical procedures were performed during PIPAC in 1.6 % of the patients. Median length of stay was 2 days. A total of 95 surgical complications were recorded, but only 22 % of these were graded ≥3b. Seventeen-hundred-and-three adverse events were noted, and 8 % were classified ≥3. The rate of complete or major histological response (peritoneal regression grade score, PRGS≤2) increased between the first and the third PIPAC in the group of patients who were evaluated by PRGS, and a PRGS ≤2 or a reduction of the mean PRGS of at least 1 between first and third PIPAC were observed in 80 %. Disease progression (50 %) or technical issues (19 %) were the most important reasons for stopping PIPAC treatment. Median overall survival from first PIPAC directed treatment varied from 10.7 months (CI 8.7–12.5) in gastric cancer to 27.1 months (16.4–50.5) in mesothelioma. Conclusions The ISSPP PIPAC database provides substantial real-world data supporting the use of PIPAC directed therapy in patients with PM from different primary tumors.
目的根据国际胸膜和腹膜研究学会(ISSPP) PIPAC数据库的数据,监测PIPAC定向治疗的结果。方法分析2020年6月15日至2023年2月28日期间入院的患者数据。结果12个中心报告了809例不同原发肿瘤腹膜转移(PM)患者的2456例PIPAC手术(中位数2例,范围1-18例)。大约90% %在PIPAC之前进行了全身化疗。28%的患者接受前瞻性治疗。总体非访问率为3.5 %。1.6 %的患者在PIPAC期间进行了伴随手术。中位住院时间为2天。共记录了95例手术并发症,但其中只有22% %分级≥3b。不良事件1703例,8 %分级≥3级。在接受PRGS评估的患者组中,第一次和第三次PIPAC之间的完全或主要组织学缓解率(腹膜消退等级评分,PRGS≤2)增加,PRGS≤2或第一次和第三次PIPAC之间平均PRGS降低至少1的比例为80% %。疾病进展(50% %)或技术问题(19% %)是停止PIPAC治疗的最重要原因。首次PIPAC治疗的中位总生存期从胃癌的10.7个月(CI 8.7-12.5)到间皮瘤的27.1个月(CI 16.4-50.5)不等。ISSPP PIPAC数据库提供了大量的真实数据,支持PIPAC指导治疗来自不同原发肿瘤的PM患者。
{"title":"Second annual report from the ISSPP PIPAC database","authors":"Michael Bau Mortensen, Francesco Casella, Özgül Düzgün, Olivier Glehen, Peter Hewett, Martin Hübner, Magnus Skov Jørgensen, Alfred Königsrainer, Miguel Marin, M. Pocard, Günther Rezniczek, Jimmy So, C. Fristrup","doi":"10.1515/pp-2023-0047","DOIUrl":"https://doi.org/10.1515/pp-2023-0047","url":null,"abstract":"Abstract Objectives To monitor the results of PIPAC directed therapy based on data from the International Society for the Study of the Pleura and Peritoneum (ISSPP) PIPAC database. Methods Analysis of data from patients entered between June 15th, 2020, and February 28th, 2023. Results Twelve centers reported 2,456 PIPAC procedures in 809 patients (median 2, range 1–18) with peritoneal metastasis (PM) from different primary tumors. Approximately 90 % had systemic chemotherapy prior to PIPAC. Twenty-eight percent were treated in prospective protocols. Overall non-access rate was 3.5 %. Concomitant surgical procedures were performed during PIPAC in 1.6 % of the patients. Median length of stay was 2 days. A total of 95 surgical complications were recorded, but only 22 % of these were graded ≥3b. Seventeen-hundred-and-three adverse events were noted, and 8 % were classified ≥3. The rate of complete or major histological response (peritoneal regression grade score, PRGS≤2) increased between the first and the third PIPAC in the group of patients who were evaluated by PRGS, and a PRGS ≤2 or a reduction of the mean PRGS of at least 1 between first and third PIPAC were observed in 80 %. Disease progression (50 %) or technical issues (19 %) were the most important reasons for stopping PIPAC treatment. Median overall survival from first PIPAC directed treatment varied from 10.7 months (CI 8.7–12.5) in gastric cancer to 27.1 months (16.4–50.5) in mesothelioma. Conclusions The ISSPP PIPAC database provides substantial real-world data supporting the use of PIPAC directed therapy in patients with PM from different primary tumors.","PeriodicalId":20231,"journal":{"name":"Pleura and Peritoneum","volume":"49 3","pages":""},"PeriodicalIF":1.8,"publicationDate":"2023-12-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138633039","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
What is long-term survival in patients with peritoneal metastasis from gastric, pancreatic, or colorectal cancer? A study of patients treated with systemic chemotherapy and pressurized intraperitoneal aerosol chemotherapy (PIPAC) 胃癌、胰腺癌或结直肠癌腹膜转移患者的长期生存率如何?对接受全身化疗和腹腔内加压气溶胶化疗 (PIPAC) 患者的研究
IF 1.8 Q4 ONCOLOGY Pub Date : 2023-12-01 DOI: 10.1515/pp-2023-0038
Charlotte G. Kryh-Jensen, C. Fristrup, Alan P. Ainsworth, S. Detlefsen, Michael B. Mortensen, Per Pfeiffer, L. Tarpgaard, M. Graversen
Abstract Objectives A definition of long-term survival (LTS) in patients with peritoneal metastasis (PM) from gastric cancer (GC), pancreatic cancer (PC) or colorectal cancer (CRC) treated with systemic chemotherapy and pressurized intraperitoneal aerosol chemotherapy (PIPAC) is lacking. We aimed to define LTS and investigate characteristics and treatment response in patients who reached LTS in data from two prospective trials. Methods Retrospective study of patients with GC-, PC-, or CRC-PM from the prospective PIPAC-OPC1 and PIPAC-OPC2 studies. The definition of LTS was based on published systematic reviews and randomized controlled trials. LTS was defined at the time point where 25 % of the patients were alive in these studies. Histology based response was evaluated by the mean Peritoneal Regression Grading Score (PRGS) using biopsies obtained prior to PIPAC 3, and defined by a mean PRGS of ≤2.0 or a decrease of mean PRGS of ≥1, compared to baseline. Results LTS was defined at 21 (GC), 15 (PC), and 24 (CRC) months. Fifty-one (47.2 %) patients (nine GC, 17 PC, 25 CRC) reached LTS calculated from the date of PM diagnosis. All but one received palliative chemotherapy before PIPAC, and 37 % received bidirectional treatment. More than 90 % of the LTS patients had response according to PRGS. The mOS from PIPAC 1 was 23.3, 12.4, and 28.5 months for GC, PC, and CRC LTS patients. Conclusions Patients with PM from GC, PC, and CRC treated with systemic chemotherapy and PIPAC can reach LTS and most show histological response. Causality must be further investigated.
摘要 目的 缺乏对胃癌(GC)、胰腺癌(PC)或结直肠癌(CRC)腹膜转移(PM)患者接受全身化疗和加压腹腔内气溶胶化疗(PIPAC)后长期生存(LTS)的定义。我们旨在定义LTS,并调查两项前瞻性试验数据中达到LTS的患者的特征和治疗反应。方法 对前瞻性 PIPAC-OPC1 和 PIPAC-OPC2 研究中的 GC、PC 或 CRC-PM 患者进行回顾性研究。LTS 的定义基于已发表的系统综述和随机对照试验。在这些研究中,LTS 的定义为 25% 的患者存活的时间点。组织学反应根据 PIPAC 3 之前获得的活组织切片的平均腹膜回归分级评分(PRGS)进行评估,平均 PRGS 与基线相比≤2.0 或平均 PRGS 降低≥1。结果 LTS 的定义时间分别为 21 个月(GC)、15 个月(PC)和 24 个月(CRC)。51例(47.2%)患者(9 例 GC、17 例 PC、25 例 CRC)从 PM 诊断之日起计算达到了 LTS。除一名患者外,其他患者均在 PIPAC 前接受了姑息化疗,37% 的患者接受了双向治疗。根据 PRGS,90% 以上的 LTS 患者有反应。GC、PC 和 CRC LTS 患者自 PIPAC 1 起的生存期分别为 23.3 个月、12.4 个月和 28.5 个月。结论 接受全身化疗和 PIPAC 治疗的 GC、PC 和 CRC PM 患者可达到 LTS,且大多数患者表现出组织学反应。其因果关系有待进一步研究。
{"title":"What is long-term survival in patients with peritoneal metastasis from gastric, pancreatic, or colorectal cancer? A study of patients treated with systemic chemotherapy and pressurized intraperitoneal aerosol chemotherapy (PIPAC)","authors":"Charlotte G. Kryh-Jensen, C. Fristrup, Alan P. Ainsworth, S. Detlefsen, Michael B. Mortensen, Per Pfeiffer, L. Tarpgaard, M. Graversen","doi":"10.1515/pp-2023-0038","DOIUrl":"https://doi.org/10.1515/pp-2023-0038","url":null,"abstract":"Abstract Objectives A definition of long-term survival (LTS) in patients with peritoneal metastasis (PM) from gastric cancer (GC), pancreatic cancer (PC) or colorectal cancer (CRC) treated with systemic chemotherapy and pressurized intraperitoneal aerosol chemotherapy (PIPAC) is lacking. We aimed to define LTS and investigate characteristics and treatment response in patients who reached LTS in data from two prospective trials. Methods Retrospective study of patients with GC-, PC-, or CRC-PM from the prospective PIPAC-OPC1 and PIPAC-OPC2 studies. The definition of LTS was based on published systematic reviews and randomized controlled trials. LTS was defined at the time point where 25 % of the patients were alive in these studies. Histology based response was evaluated by the mean Peritoneal Regression Grading Score (PRGS) using biopsies obtained prior to PIPAC 3, and defined by a mean PRGS of ≤2.0 or a decrease of mean PRGS of ≥1, compared to baseline. Results LTS was defined at 21 (GC), 15 (PC), and 24 (CRC) months. Fifty-one (47.2 %) patients (nine GC, 17 PC, 25 CRC) reached LTS calculated from the date of PM diagnosis. All but one received palliative chemotherapy before PIPAC, and 37 % received bidirectional treatment. More than 90 % of the LTS patients had response according to PRGS. The mOS from PIPAC 1 was 23.3, 12.4, and 28.5 months for GC, PC, and CRC LTS patients. Conclusions Patients with PM from GC, PC, and CRC treated with systemic chemotherapy and PIPAC can reach LTS and most show histological response. Causality must be further investigated.","PeriodicalId":20231,"journal":{"name":"Pleura and Peritoneum","volume":"990 1","pages":"147 - 155"},"PeriodicalIF":1.8,"publicationDate":"2023-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139019425","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Genital cutaneous necrosis: a delayed sequela of intraperitoneal Mitomycin-c 生殖器皮肤坏死:腹膜内注射丝裂霉素c的延迟后遗症
Q4 ONCOLOGY Pub Date : 2023-10-13 DOI: 10.1515/pp-2023-0021
Sage A. Vincent, Meghan Maceyko, Peter J. Altshuler, Zachary Davis, J. Ryan Mark, Paul H. Chung, Wilbur B. Bowne
{"title":"Genital cutaneous necrosis: a delayed sequela of intraperitoneal Mitomycin-c","authors":"Sage A. Vincent, Meghan Maceyko, Peter J. Altshuler, Zachary Davis, J. Ryan Mark, Paul H. Chung, Wilbur B. Bowne","doi":"10.1515/pp-2023-0021","DOIUrl":"https://doi.org/10.1515/pp-2023-0021","url":null,"abstract":"","PeriodicalId":20231,"journal":{"name":"Pleura and Peritoneum","volume":"251 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-10-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135805251","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Abdominal tuberculosis mimicking peritoneal metastasis. 模拟腹膜转移的腹部结核。
IF 1.8 Q4 ONCOLOGY Pub Date : 2023-09-01 DOI: 10.1515/pp-2023-0012
Ragad I Al Jazzar, Zeinah Sulaihim, Ahmad Alkhiary, Nayef Alzahrani
Peritoneal tuberculosis is a rare form of extrapulmonary tuberculosis. This challenge is attributed to its great mimicry of other peritoneal disease processes along with its nonspeci fi c clinical presentation. We report a case of a 60-year old man, known case of rectosigmoid cancer with liver and lung nodules. Status post low anterior resection,
{"title":"Abdominal tuberculosis mimicking peritoneal metastasis.","authors":"Ragad I Al Jazzar,&nbsp;Zeinah Sulaihim,&nbsp;Ahmad Alkhiary,&nbsp;Nayef Alzahrani","doi":"10.1515/pp-2023-0012","DOIUrl":"https://doi.org/10.1515/pp-2023-0012","url":null,"abstract":"Peritoneal tuberculosis is a rare form of extrapulmonary tuberculosis. This challenge is attributed to its great mimicry of other peritoneal disease processes along with its nonspeci fi c clinical presentation. We report a case of a 60-year old man, known case of rectosigmoid cancer with liver and lung nodules. Status post low anterior resection,","PeriodicalId":20231,"journal":{"name":"Pleura and Peritoneum","volume":"8 3","pages":"139-140"},"PeriodicalIF":1.8,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10469162/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10137336","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Prognostic value of preoperative serological biomarkers in patients undergoing cytoreductive surgery for ovarian cancer peritoneal metastases. 术前血清学生物标志物在卵巢癌腹膜转移患者行细胞减缩手术中的预后价值。
IF 1.8 Q4 ONCOLOGY Pub Date : 2023-09-01 DOI: 10.1515/pp-2022-0199
Charif Khaled, Antoine El Asmar, Omar Raisi, Michel Moreau, Laura Polastro, Isabelle Veys, Florin C Pop, Vincent Donckier, Gabriel Liberale

Objectives: Peritoneal metastases of ovarian cancer (PMOC) are common at initial presentation. Cytoreductive surgery (CRS) of curative intent has been proven to be efficient in increasing the overall survival (OS) and the disease-free survival (DFS) of these patients. Nevertheless, CRS is associated with high postoperative morbidity, which makes patient selection a major concern. Appropriate prognostic factors that can predict patient outcomes after surgery are still lacking. Preoperative biomarkers and their ratios have been shown to be predictive of patient prognosis for various solid tumors. We aimed to study their correlation with the prognosis of patients undergoing CRS for PMOC.

Methods: This retrospective study included patients with PMOC operated by CRS. Preoperative biomarkers and other clinicopathological characteristics were studied to determine their prognostic value in terms OS and DFS.

Results: 216 patients were included. Patients with preoperative hemoglobin (Hb) <11.7 g/dL had a poorer prognosis in terms of OS (p=0.0062) and DFS (p=0.0077). Additionally, increased neutrophil-to-lymphocyte ratio (NLR), monocyte-to-lymphocyte ratio (MLR) >0.32, and platelet-to-lymphocyte ratio (PLR) >214.5 were associated with worse OS (p=0.022, p=0.0028, and p=0.0018, respectively) and worse DFS (p=0.028, p=0.003, and p=0.019, respectively). Multivariate analysis showed that the variables mentioned above were independent predictive factors for OS and DFS.

Conclusions: Preoperative Hb level, NLR, MLR, and PLR are prognostic factors for OS and DFS in PMOC patients operated by curative CRS.

目的:卵巢癌腹膜转移(PMOC)在最初的表现是常见的。具有治疗目的的细胞减少手术(CRS)已被证明可有效提高这些患者的总生存期(OS)和无病生存期(DFS)。然而,CRS与术后高发病率相关,这使得患者选择成为一个主要问题。目前仍缺乏能够预测手术后患者预后的适当预后因素。术前生物标志物及其比值已被证明可以预测各种实体瘤的预后。我们的目的是研究它们与PMOC患者接受CRS的预后的相关性。方法:回顾性研究采用CRS手术的PMOC患者。研究术前生物标志物和其他临床病理特征,以确定其在OS和DFS方面的预后价值。结果:共纳入216例患者。术前血红蛋白(Hb) 0.32、血小板与淋巴细胞比值(PLR) >214.5的患者,OS加重(p=0.022、p=0.0028、p=0.0018), DFS加重(p=0.028、p=0.003、p=0.019)。多因素分析表明,上述变量是OS和DFS的独立预测因素。结论:术前Hb水平、NLR、MLR和PLR是治疗性CRS手术PMOC患者OS和DFS的预后因素。
{"title":"Prognostic value of preoperative serological biomarkers in patients undergoing cytoreductive surgery for ovarian cancer peritoneal metastases.","authors":"Charif Khaled,&nbsp;Antoine El Asmar,&nbsp;Omar Raisi,&nbsp;Michel Moreau,&nbsp;Laura Polastro,&nbsp;Isabelle Veys,&nbsp;Florin C Pop,&nbsp;Vincent Donckier,&nbsp;Gabriel Liberale","doi":"10.1515/pp-2022-0199","DOIUrl":"https://doi.org/10.1515/pp-2022-0199","url":null,"abstract":"<p><strong>Objectives: </strong>Peritoneal metastases of ovarian cancer (PMOC) are common at initial presentation. Cytoreductive surgery (CRS) of curative intent has been proven to be efficient in increasing the overall survival (OS) and the disease-free survival (DFS) of these patients. Nevertheless, CRS is associated with high postoperative morbidity, which makes patient selection a major concern. Appropriate prognostic factors that can predict patient outcomes after surgery are still lacking. Preoperative biomarkers and their ratios have been shown to be predictive of patient prognosis for various solid tumors. We aimed to study their correlation with the prognosis of patients undergoing CRS for PMOC.</p><p><strong>Methods: </strong>This retrospective study included patients with PMOC operated by CRS. Preoperative biomarkers and other clinicopathological characteristics were studied to determine their prognostic value in terms OS and DFS.</p><p><strong>Results: </strong>216 patients were included. Patients with preoperative hemoglobin (Hb) <11.7 g/dL had a poorer prognosis in terms of OS (p=0.0062) and DFS (p=0.0077). Additionally, increased neutrophil-to-lymphocyte ratio (NLR), monocyte-to-lymphocyte ratio (MLR) >0.32, and platelet-to-lymphocyte ratio (PLR) >214.5 were associated with worse OS (p=0.022, p=0.0028, and p=0.0018, respectively) and worse DFS (p=0.028, p=0.003, and p=0.019, respectively). Multivariate analysis showed that the variables mentioned above were independent predictive factors for OS and DFS.</p><p><strong>Conclusions: </strong>Preoperative Hb level, NLR, MLR, and PLR are prognostic factors for OS and DFS in PMOC patients operated by curative CRS.</p>","PeriodicalId":20231,"journal":{"name":"Pleura and Peritoneum","volume":"8 3","pages":"133-138"},"PeriodicalIF":1.8,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10469179/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10142844","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Investigation of the effectiveness of hyperthermic intraperitoneal chemotherapy in experimental colorectal peritoneal metastasis model. 腹腔热化疗对实验性大肠癌腹膜转移模型的影响。
IF 1.8 Q4 ONCOLOGY Pub Date : 2023-09-01 DOI: 10.1515/pp-2023-0002
Berke Manoğlu, Tuğba Yavuzşen, Safiye Aktaş, Zekiye Altun, Osman Yılmaz, Özde Elif Gökbayrak, Aylin Erol

Objectives: In our study, we aimed to (1) create a peritoneal metastasis (PM) model in nude mice, administer intraperitoneal chemotherapy using the peritoneal infusion pump we developed in this model, and (2) compare the efficacy of intraperitoneal chemotherapy using various drugs at different temperatures.

Methods: The peritoneal metastasis model was established in nude mice using the CC531 colon carcinoma cell line. Models with peritoneal metastasis (PM) were randomized into four groups of seven animals each: Group 1, control group (n=7); Group 2, normothermic intraperitoneal chemotherapy (NIPEC) with mitomycin C(MMC) (n=7); Group 3, hyperthermic intraperitoneal chemotherapy (HIPEC) with mitomycin C (n=7), and Group 4, NIPEC with 5-fluorouracil (5-FU).

Results: Tumor development was achieved in all animals. While the tumor burden decreased significantly in the treatment Group 3 (p=0.034), no significant difference was found in the other groups. In the PM mouse model, hyperthermic intraperitoneal administration of MMC had the highest tumoricidal effect.

Conclusions: Our PM model provided a good opportunity to examine the efficacy of HIPEC and intraperitoneal infusion pump (IPIP). In future studies, we plan to evaluate efficacies of different drugs in the PM models we have created.

目的:在我们的研究中,我们的目的是(1)建立裸鼠腹膜转移(PM)模型,使用我们在该模型中开发的腹膜输注泵进行腹腔化疗,(2)比较不同温度下不同药物腹腔化疗的效果。方法:采用CC531结肠癌细胞系建立裸鼠腹膜转移模型。腹腔转移模型随机分为4组,每组7只:1组,对照组(n=7);2组,常温腹腔化疗(NIPEC)联合丝裂霉素C(MMC) (n=7);第3组采用丝裂霉素C腹腔热化疗(HIPEC) (n=7),第4组采用5-氟尿嘧啶腹腔热化疗(NIPEC) (5-FU)。结果:所有动物均有肿瘤发生。治疗组3肿瘤负荷明显降低(p=0.034),其他组间差异无统计学意义。在PM小鼠模型中,温热腹腔注射MMC具有最高的肿瘤杀伤作用。结论:我们的PM模型提供了一个很好的机会来检验HIPEC和腹腔内输液泵(IPIP)的疗效。在未来的研究中,我们计划在我们创建的PM模型中评估不同药物的疗效。
{"title":"Investigation of the effectiveness of hyperthermic intraperitoneal chemotherapy in experimental colorectal peritoneal metastasis model.","authors":"Berke Manoğlu,&nbsp;Tuğba Yavuzşen,&nbsp;Safiye Aktaş,&nbsp;Zekiye Altun,&nbsp;Osman Yılmaz,&nbsp;Özde Elif Gökbayrak,&nbsp;Aylin Erol","doi":"10.1515/pp-2023-0002","DOIUrl":"https://doi.org/10.1515/pp-2023-0002","url":null,"abstract":"<p><strong>Objectives: </strong>In our study, we aimed to (1) create a peritoneal metastasis (PM) model in nude mice, administer intraperitoneal chemotherapy using the peritoneal infusion pump we developed in this model, and (2) compare the efficacy of intraperitoneal chemotherapy using various drugs at different temperatures.</p><p><strong>Methods: </strong>The peritoneal metastasis model was established in nude mice using the CC531 colon carcinoma cell line. Models with peritoneal metastasis (PM) were randomized into four groups of seven animals each: Group 1, control group (n=7); Group 2, normothermic intraperitoneal chemotherapy (NIPEC) with mitomycin C(MMC) (n=7); Group 3, hyperthermic intraperitoneal chemotherapy (HIPEC) with mitomycin C (n=7), and Group 4, NIPEC with 5-fluorouracil (5-FU).</p><p><strong>Results: </strong>Tumor development was achieved in all animals. While the tumor burden decreased significantly in the treatment Group 3 (p=0.034), no significant difference was found in the other groups. In the PM mouse model, hyperthermic intraperitoneal administration of MMC had the highest tumoricidal effect.</p><p><strong>Conclusions: </strong>Our PM model provided a good opportunity to examine the efficacy of HIPEC and intraperitoneal infusion pump (IPIP). In future studies, we plan to evaluate efficacies of different drugs in the PM models we have created.</p>","PeriodicalId":20231,"journal":{"name":"Pleura and Peritoneum","volume":"8 3","pages":"123-131"},"PeriodicalIF":1.8,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10469180/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10524103","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Early postoperative CRP predicts major complications following cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC). 术后早期CRP可预测细胞减少手术(CRS)和腹腔热化疗(HIPEC)后的主要并发症。
IF 1.8 Q4 ONCOLOGY Pub Date : 2023-09-01 DOI: 10.1515/pp-2022-0203
Akash Kartik, Catharina Müller, Miklos Acs, Pompiliu Piso, Patrick Starlinger, Thomas Bachleitner-Hofmann, Travis E Grotz

Objectives: Cytoreductive surgery (CRS) and heated intraperitoneal chemotherapy (HIPEC) is associated with significant postoperative complications. Early detection of at-risk patients may lead to improved outcomes. The role of C-reactive protein (CRP) in predicting postoperative complications has only been recently investigated.

Methods: Postoperative complications were categorized according to Clavien-Dindo classification and further divided into minor (Grade <3) and major complications (Grade ≥3A). Absolute CRP counts (mg/L) on postoperative days (POD) 1-7, and proportional change in CRP was compared and the area under (AUC) receiver operating characteristics (ROC) curve was calculated. Univariate and multivariate analysis was performed. Significant findings were externally validated.

Results: Twenty-five percent of patients experienced one or more major complications. A CRP level of ≥106 mg/L on POD 2 and 65.5 mg/L on POD 4 were significantly associated with an increased risk of major complications with an AUC of 0.658 and 0.672, respectively. The proportional increase in CRP between POD 1 and 4 (ΔCRP POD 1/4) at a cut-off of 30 % had the best AUC of 0.744 and was the only independent risk factor for major complications (p<0.0001) on multivariate analysis. ∆CRP had an AUC of 0.716 (p=0.002) when validated in an independent database.

Conclusions: CRP can be used in a variety of ways to predict major complications after CRS and HIPEC. However, the ∆CRP POD 1/4>30 % is the best indicator of major complications. Serial CRP measurements in the early postoperative period may lead to early detection of patients at risk of major complications allowing for alternative management strategies to improve outcomes.

目的:细胞减少手术(CRS)和腹腔内加热化疗(HIPEC)与显著的术后并发症相关。早期发现高危患者可能会改善预后。c反应蛋白(CRP)在预测术后并发症中的作用直到最近才被研究。方法:术后并发症按照Clavien-Dindo分类进行分类,并进一步分为轻微并发症(分级结果:25%的患者出现一种或多种主要并发症。POD 2上CRP水平≥106 mg/L和POD 4上CRP水平≥65.5 mg/L与主要并发症风险增加显著相关,AUC分别为0.658和0.672。CRP在POD 1和4 (ΔCRP POD 1/4)之间的比例增加(截点为30 %)的最佳AUC为0.744,是主要并发症的唯一独立危险因素(结论:CRP可用于多种方法预测CRS和HIPEC后的主要并发症。然而,∆CRP POD 1/4>30 %是主要并发症的最佳指标。术后早期连续测量CRP可能导致早期发现有主要并发症风险的患者,从而允许采用其他管理策略来改善预后。
{"title":"Early postoperative CRP predicts major complications following cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC).","authors":"Akash Kartik,&nbsp;Catharina Müller,&nbsp;Miklos Acs,&nbsp;Pompiliu Piso,&nbsp;Patrick Starlinger,&nbsp;Thomas Bachleitner-Hofmann,&nbsp;Travis E Grotz","doi":"10.1515/pp-2022-0203","DOIUrl":"https://doi.org/10.1515/pp-2022-0203","url":null,"abstract":"<p><strong>Objectives: </strong>Cytoreductive surgery (CRS) and heated intraperitoneal chemotherapy (HIPEC) is associated with significant postoperative complications. Early detection of at-risk patients may lead to improved outcomes. The role of C-reactive protein (CRP) in predicting postoperative complications has only been recently investigated.</p><p><strong>Methods: </strong>Postoperative complications were categorized according to Clavien-Dindo classification and further divided into minor (Grade <3) and major complications (Grade ≥3A). Absolute CRP counts (mg/L) on postoperative days (POD) 1-7, and proportional change in CRP was compared and the area under (AUC) receiver operating characteristics (ROC) curve was calculated. Univariate and multivariate analysis was performed. Significant findings were externally validated.</p><p><strong>Results: </strong>Twenty-five percent of patients experienced one or more major complications. A CRP level of ≥106 mg/L on POD 2 and 65.5 mg/L on POD 4 were significantly associated with an increased risk of major complications with an AUC of 0.658 and 0.672, respectively. The proportional increase in CRP between POD 1 and 4 (ΔCRP POD 1/4) at a cut-off of 30 % had the best AUC of 0.744 and was the only independent risk factor for major complications (p<0.0001) on multivariate analysis. ∆CRP had an AUC of 0.716 (p=0.002) when validated in an independent database.</p><p><strong>Conclusions: </strong>CRP can be used in a variety of ways to predict major complications after CRS and HIPEC. However, the ∆CRP POD 1/4>30 % is the best indicator of major complications. Serial CRP measurements in the early postoperative period may lead to early detection of patients at risk of major complications allowing for alternative management strategies to improve outcomes.</p>","PeriodicalId":20231,"journal":{"name":"Pleura and Peritoneum","volume":"8 3","pages":"113-121"},"PeriodicalIF":1.8,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10468822/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10142843","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Embryological, anatomical and clinical considerations on pleuroperitoneal communication. 胸膜-腹膜沟通的胚胎学、解剖学和临床考虑。
IF 1.8 Q4 ONCOLOGY Pub Date : 2023-09-01 DOI: 10.1515/pp-2023-0013
Christodoulos Chatzigrigoriadis, Anastasios Goulioumis, Despoina Sperdouli, Kostis Gyftopoulos

The pleural and peritoneal cavity share many related features due to their common celomic origin. Normally these two spaces are completely separated with the development of the diaphragm. Defects in diaphragm morphogenesis may result in congenital diaphragmatic hernias, which is the most known form of communication between the pleural and peritoneal cavity. However, in several cases, findings of pleuroperitoneal communication (PPC) have been described in adults through an apparently intact diaphragm. In this comprehensive review we systematically evaluate clinical scenarios of this form of "unexpected" PPC as reported in the literature and focus on the possible mechanisms involved.

胸膜腔和腹膜腔由于其共同的经济起源而具有许多相关的特征。通常这两个空间是完全分开的隔膜的发展。横膈膜形态发生的缺陷可能导致先天性膈疝,这是胸膜和腹膜腔之间最常见的沟通形式。然而,在一些病例中,发现胸膜腹膜通信(PPC)在成人通过一个明显完整的横膈膜。在这篇全面的综述中,我们系统地评估了文献中报道的这种形式的“意外”PPC的临床情况,并重点关注可能涉及的机制。
{"title":"Embryological, anatomical and clinical considerations on pleuroperitoneal communication.","authors":"Christodoulos Chatzigrigoriadis,&nbsp;Anastasios Goulioumis,&nbsp;Despoina Sperdouli,&nbsp;Kostis Gyftopoulos","doi":"10.1515/pp-2023-0013","DOIUrl":"https://doi.org/10.1515/pp-2023-0013","url":null,"abstract":"<p><p>The pleural and peritoneal cavity share many related features due to their common celomic origin. Normally these two spaces are completely separated with the development of the diaphragm. Defects in diaphragm morphogenesis may result in congenital diaphragmatic hernias, which is the most known form of communication between the pleural and peritoneal cavity. However, in several cases, findings of pleuroperitoneal communication (PPC) have been described in adults through an apparently intact diaphragm. In this comprehensive review we systematically evaluate clinical scenarios of this form of \"unexpected\" PPC as reported in the literature and focus on the possible mechanisms involved.</p>","PeriodicalId":20231,"journal":{"name":"Pleura and Peritoneum","volume":"8 3","pages":"101-111"},"PeriodicalIF":1.8,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10469182/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10151308","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Pleura and Peritoneum
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1